Bluebird myeloma treatment delays cancer progression: trial

CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.

from Reuters: Health News https://ift.tt/2LdeQiE